Abstract:Background: Schizophrenia (SCZ) is a serious psychiatric illness accompanied by a decline in neurocognitive abilities. The metabolic abnormalities are associated with the pathophysiology of SCZ. Yet the effectiveness of current therapeutic strategies for SCZ remains debatable. To investigate the potential causal relationships between blood metabolites, SCZ and relevant neurocognitive abilities using genetically based methods for assessing potentially causal inference.Methods: We collected 29 blood metabolites (N = 13,476 to 215,551 subjects) that have been reported for correlation with SCZ or relevant neurocognitive traits, then we conducted bidirectional two-sample Mendelian Randomization (MR) analyses of these metabolites with SCZ (N = 130,644) and 6 relevant neurocognitive traits (N = 168,033 to 332,050) from large-scale genome-wide association studies of European ancestry. Mediation analysis was used to explore potential causal pathways between the putative causal metabolites and SCZ, as well as neurocognitive traits.Findings: MR evidences supported a protective causal role of docosahexaenoic acid (ORIVW = 0.83, 95% CI 0.75 to 0.91) and acetylornithine on SCZ (ORIVW = 0.83, 95% CI 0.76 to 0.90) and an adverse causal role of butyrylcarnitine on SCZ (ORIVW = 1.09, 95% CI 1.04 to 1.14). Mediation analysis identified potential causal pathways from acetylornithine or butyrylcarnitine through neurocognitive traits to SCZ.Interpretation: Our study will support associations of blood metabolites with the risk of SCZ, and neurocognitive abilities may involve in this effect. These findings may hold novel prospects for treatments and interventions for SCZ.Funding: The authors declare that they have no conflict of interest.Declaration of Interest: This work was supported by grants from the National Natural Science Foundation of China (grant nos. 32170616 (T.-L.Y.), 82170896 (Y.G), 31970569 (Y.G) and 82101601 (S.Y.)), Science Fund for Distinguished Young Scholars of Shaanxi Province (grant no. 2021JC-02 (T.-L.Y.)). This work was also supported by the High- Performance Computing Platform and Instrument Analysis Center of Xi’an Jiaotong University. We thank the UK Biobank Resource under the application number 46387. The GWAS summary data of blood lipids (HDL-C, LDL-C, TG and TC) we used were available from dbGaP (http://www.ncbi.nlm.nih.gov/gap) under accession number phs001672.v4.p1.

Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations

Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits

Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach

Genome-wide Association Study of Monoamine Metabolite Levels in Human Cerebrospinal Fluid

Mass spectrometry for biomarkers, disease mechanisms, and drug development in cerebrospinal fluid metabolomics

Mendelian randomization study of causal link from Cerebrospinal fluid metabolomics to neurodegenerative diseases

Evaluating metabolome-wide causal effects on risk for psychiatric and neurodegenerative disorders

Cerebrospinal Fluid and Plasma Metabolites with Parkinson's Disease: A Mendelian Randomization Study

Novel genetic associations with serum level metabolites identified by phenotype set enrichment analyses.

Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease

Elucidation of the complex metabolic profile of cerebrospinal fluid using an untargeted biochemical profiling assay.

Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy

Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

Mendelian Randomization Analysis of the Brain, Cerebrospinal Fl Uid, and Plasma Proteome Identi Fi Es Potential Drug Targets for Attention De Fi Cit Hyperactivity Disorder

Assessing the Causal Effects of Human Serum Metabolites on 5 Major Psychiatric Disorders

Characterizing the Causal Associations Between Blood Metabolites, Schizophrenia and Neurocognitive Traits Using a Mendelian Randomization Study

Cerebrospinal fluid metabolite alterations in patients with different etiologies, diagnoses, and prognoses of disorders of consciousness

Cerebrospinal fluid proteomic signatures are associated with symptom severity of first-episode psychosis

A Comprehensive Evaluation of Cross-Omics Blood-Based Biomarkers for Neuropsychiatric Disorders

Liquid chromatography coupled to mass spectrometry metabolomic analysis of cerebrospinal fluid revealed the metabolic characteristics of moyamoya disease

Association between human blood metabolites and cerebral cortex architecture: evidence from a Mendelian randomization study